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Background: The objective of this study was to evaluate the effectiveness of a clinical decision support system (CDSS) for reducing use of drugs 
known to cause drug-induced torsades de pointes (TdP) and decreasing the risk of QTc interval prolongation in hospitalized patients with known TdP 
risk factors.
Methods: We evaluated 2400 patients admitted to cardiac comprehensive care units at an urban academic medical center over a 1-year period. 
Patients were excluded if they were < 18 years of age or underwent continuous ventricular pacing. A CDSS incorporating a validated risk score for 
corrected QT (QTc) interval prolongation was developed and implemented using patients’ electronic medical records. When a drug known to cause 
TdP was prescribed to a patient at moderate or high risk for QTc interval prolongation, a computer alert appeared to the pharmacist entering the 
order, who could then choose to override the alert and provide the medication, or consult the prescribing physician and/or implement additional 
monitoring, including laboratory tests. QTc intervals were measured within 4 hours of admission and at least daily until discharge. QTc prolongation 
was defined as QTc interval > 500 ms or increase in QTc of ≥ 60 ms from admitting value. Endpoints were assessed prior to (n=1200) and after 
(n=1200) implementation of the CDSS. Univariate analyses were performed on variables including demographics, comorbidities, medications, and 
utilization of the CDSS. Variables with p values ≤ 0.10 were included in the multivariate regression model. 
Results: In patients with TdP risk factors, implementation of the CDSS independently reduced the prescribing of medications known to cause TdP, 
including fluoroquinolones, fluconazole, haloperidol, methadone, macrolides or antipsychotics (odds ratio 0.85, 95% confidence interval 0.67-0.99). 
Utilization of the CDSS was independently associated with a reduced risk of QTc interval prolongation [0.43 (0.25-0.74)]. 
Conclusions: A computerized CDSS incorporating a validated risk score for QTc interval prolongation influences the prescribing of QT-prolonging 
drugs and reduces the risk of QTc interval prolongation in hospitalized patients with TdP risk factors.
